Control Bionics Ltd. · ASX:CBL
Control Bionics — Shareholder Meeting (October 2023)
27 slides from Control Bionics's shareholder meeting presentation, Oct 10, 2023
Slide 1: AGM Presentation
For personal use only PRESENTED BY: Roger Hawke, Chairman and Jeremy Steele, CEO DATE PRESENTED: 10 October 2023 VERSION: 1.0 Private & Confidential. Copyright © Control Bionics 2023
Slide 2: Acknowledgement of Country
Acknowledgement of Country For personal use only I begin today by acknowledging the Gadigal people of the Eora Nation, Traditional Custodians of the land on which we meet today, and pay my respects to their Elders past, present and emerging. I extend that respect to Aboriginal and Torres Strait Isla
Slide 3: Disclaimer
DISCLAIMER For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the co
Slide 4: Leadership Team
LEADERSHIP TEAM • Over 25 years of global corporate experience across a wide range of industries including healthcare and software For personal use only • Previously CEO of CardioScan, driving international BOARD expansion (from 1 to 10 countries) Jeremy Steele • Led greenfield expansion as well as
Slide 5: Our flagship product
For personal use only Our flagship product
Slide 6: Proxy voting report
461 2 9698 5414 (international) hello@automic.com.au 4) A U T (eo) M l Cc } 1300 288 664 (within australia) ABN: 27 152 260 814 www.automic.com.au = ull Voting Report imited Security Class(es): CBL - Fully Paid Shares Control Bionics Annual General Meeting Dv PROXY FORM Exclusions Abstain No Instruc
Slide 7: CEO Presentation
For personal use only CEO Presentation Jeremy Steele
Slide 8: Our Powerful Position
OUR POWERFUL POSITION For personal use only ∙ Making life changing connections has been core to our business mission since the business began ∙ Our continued advancement in technology only improves the way in which we can impact our customer’s lives ∙ Everyone involved in our business (from employee
Slide 9: Executive Summary
EXECUTIVE SUMMARY For personal use only ∙ Control Bionics (ASX:CBL) is a pioneer in the field of neuroelectric control by using smart algorithms to detect, synthesise and convert electromyography (EMG) signals into code which can interact with and control a broad range of electronic devices ∙ Follow
Slide 10: FY23 in review
FY23 in review For personal use only ∙ Thousands of lives positively impacted with more than Revenue (A$m) 300 systems sold in our key markets in FY23 7 6 ∙ FY23 revenue up an impressive 25% over FY22 5 4 3 ∙ US is the strongest market as the strength of our team 2 and time in-market delivers 1 0 St
Slide 11: Strategic Priorities for FY24
STRATEGIC PRIORITIES FOR FY24 For personal use only In May 2023 we announced our strategic pillars for FY24, they were: ∙ Drive growth in the US to reach monthly breakeven ∙ Accelerate growth in Australia ∙ Deliver first commercial sales of DROVE ∙ Drive Neuronode sales globally as an unbundled acce
Slide 12: Strategic Priorities for FY24
STRATEGIC PRIORITIES FOR FY24 For personal use only Since May we have made progress on a number of fronts in our strategic pillars, most notably: ∙ Strong Q4FY23 sales for both the US and Australia including large wins from groups such as MND Qld ∙ Finalising comprehensive safety and electrical test
Slide 13: FY24 Outlook
FY24 Outlook For personal use only Revenue (A$m) ∙ Forecasting organic revenue growth in excess of 30% over FY23 in 9 8 existing business – accelerating our growth rate 7 6 5 ∙ Further revenue growth opportunities above this forecast include 4 3 ∙ First commercial sales of DROVE as we build towards
Slide 14: Technology Review
TECHNOLOGY REVIEW For personal use only ∙ At our core we are a technology business ∙ Innovation in our hardware and software is key to ensuring profitable growth and strengthening of our market position ∙ These are our current suite of products sold into the Augmentative and Assistive Communications
Slide 15: Technology Review
TECHNOLOGY REVIEW For personal use only ∙ For those in attendance today, immediately following the AGM you’ll have an opportunity to see our existing technology in action, including DROVE ∙ DROVE is a world first and its development assisted CBL to be named #4 in Australia’s most innovative Healthca
Slide 16: Product Launch
PRODUCT LAUNCH For personal use only We are announcing the release of our new case system today. There are significant benefits to the business through this new design including increased competitiveness, additional sales (particularly in the US), greater features and it is a more robust design. Fea
Slide 17: Technology Review: Software development
Technology Review For personal use only Software development ∙ We’ve significantly ‘upped our game’ in software with new dedicated resources and new software releases since we launched this initiative May 2023 ∙ Accomplishments include new iOS controller App, bringing inhouse all our core code base
Slide 18: Product Launch
PRODUCT LAUNCH For personal use only ∙ We’ve talked over the last 18 months about further miniaturisation of our core IP, our EMG device the NeuroNode ∙ This unique TGA/FDA/CE Mark approved device combined accelerometer and EMG device is truly an innovation developed within the company ∙ I’m excited
Slide 19: NeuroStrip
NeuroStrip For personal use only ∙ Allows users increased choice of placement and ease of use for a device that is light and flexible ∙ More sensitive readings improving useability and use cases for medical applications and other uses outside the disability market ∙ EOG, ECG, EMG (and potentially el
Slide 20: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only ∙ We are a well-established business in the Augmentative and Assistive Communications (‘AAC’) market with substantial operations in the US, Australia and opportunities in Japan ∙ Recent product innovations in hardware and software will enhance the opportun
Slide 21: Thank You
THANK YOU For personal use only JEREMY STEELE jsteele@controlbionics.com +65 9011 3975 www.controlbionics.com
Slide 22: Chief Executive Officer Address
Chief Executive Officer Address AGM 10 October 2023 Slide 7 I’d like to join our Chairman, Roger Hawke, in welcoming our shareholders to today’s AGM. As you are no doubt aware, this is my first AGM, having commenced in January this year, and I’d like to thank the board and shareholders for their ong
Slide 23: For personal use only
Slide 9 I’d like to now provide a short summary on the business and what I will cover in my remarks today. Control Bionics is a pioneer in the field of neuroelectric control by using smart algorithms to detect, synthesise and convert electromyography (EMG) signals into code which can interact with a
Slide 24: For personal use only
Slide 12 Since May we have made some great progress against these initiatives, most notably: ∙ Strong Q4FY23 sales for both the US and Australia including large wins from groups such as MND Qld ∙ Finalising comprehensive safety and electrical testing for DROVE in advance of TGA registration and firs
Slide 25: For personal use only
Slide 15 In April this year, we launched DROVE, our autonomous wheelchair module. For those in attendance today, I encourage you to join us immediately following the AGM where you’ll have an opportunity to see a full working DROVE wheelchair set up across the foyer. We are currently finalising our T
Slide 26: For personal use only
Slide 18 My management philosophy is very much about focusing on a small number of things and doing them really well. What attracted me to Control Bionics immediately was the strength of its core IP – the NeuroNode. This unique TGA/FDA/CE Mark approved device is largely unparralled globally. The com
Slide 27: For personal use only
To demonstrate how this gets really interesting is where intention turns into signal. Whilst I appreciate it’s hard to see from a distance, even a micro-movement is generating a signal. What I will be interested to see as we investigate more clinical use cases is how close to intention can we get fo